Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Department of Neurosurgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Front Immunol. 2021 Feb 18;11:582828. doi: 10.3389/fimmu.2020.582828. eCollection 2020.
Spinal cord astrocytomas (SCAs) account for 6-8% of all primary spinal cord tumors. For high-grade SCAs, the prognosis is often poor with conventional therapy, thus the urgent need for novel treatments to improve patient survival. Immunotherapy is a promising therapeutic strategy and has been used to treat cancer in recent years. Several clinical trials have evaluated immunotherapy for intracranial gliomas, providing evidence for immunotherapy-mediated ability to inhibit tumor growth. Given the unique microenvironment and molecular biology of the spinal cord, this review will offer new perspectives on moving toward the application of successful immunotherapy for SCAs based on the latest studies and literature. Furthermore, we will discuss the challenges associated with immunotherapy in SCAs, propose prospects for future research, and provide a periodic summary of the current state of immunotherapy for SCAs immunotherapy.
脊髓星形细胞瘤（SCA）占所有原发性脊髓肿瘤的 6-8%。对于高级别 SCA，传统治疗的预后往往较差，因此迫切需要新的治疗方法来提高患者的生存率。免疫疗法是一种很有前途的治疗策略，近年来已被用于治疗癌症。几项临床试验已经评估了免疫疗法治疗颅内神经胶质瘤，为免疫疗法介导抑制肿瘤生长的能力提供了证据。鉴于脊髓的独特微环境和分子生物学特性，本综述将根据最新的研究和文献，为将成功的免疫疗法应用于 SCA 提供新的视角。此外，我们还将讨论 SCA 免疫疗法相关的挑战，提出未来研究的前景，并定期总结 SCA 免疫疗法的现状。
